Political and economic uncertainty hangs over the industry, while major bets on metabolic and immune disease drug research are set to play out.

Scheduled for 13 weeks, the trial will assess the therapy’s safety, tolerability, and efficacy in weight loss.

The initiation of the phase 2 study is based on early-stage data, which show that patients who received VKTX's obesity pill ...

Some of the best possible returns for investors come by not going after megacaps, but instead pursuing stocks that have more ...

J.P. Morgan analyst Hardik Parikh has maintained their bullish stance on VKTX stock, giving a Buy rating today.Stay Ahead of the ...

JPMorgan keeps an Overweight rating and $80 price target on Viking Therapeutics (VKTX) after the company announced that it has initiated the ...

In a rare move, the FDA recommended a minimum of 5% weight-loss for drug developers seeking to establish the efficacy of ...

COO Marianna Mancini sold 54,215 shares of the firm’s stock in a transaction dated Monday, January 6th. The stock was sold at ...

Viking Therapeutics Inc’s profitability metrics reveal strong financial health. The company currently boasts a gross margin of -16.62%. The profit margin, also known as the revenue ratio or gross ...

Viking Therapeutics, Inc. (VKTX) closed at $42.53 in the latest trading session, marking a -0.84% move from the prior day. The stock fell short of the S&P 500, which registered a gain of 0.55% for the ...

Seeking Alpha analyst Terry Chrisomalis regards Viking Therapeutics as the most attractive M&A candidate in 2025, bolstered ...

JPMorgan highlights valuation resets for Viking and Structure Therapeutics, citing opportunities in T2D/obesity and competitive clinical data insights.